Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol-Myers Squibb Down Nine Consecutive Days, on Pace for Longest Losing Streak Since April 2018 -- Data Talk

09/16/2021 | 11:29am EDT

Bristol-Myers Squibb Company (BMY) is currently at $60.78, down $1.23 or 1.98%

-- Would be lowest close since March 12, 2021, when it closed at $60.64

-- Currently down 11 of the past 12 days

-- Currently down nine consecutive days; down 8.08% over this period

-- Longest losing streak since April 23, 2018, when it fell for nine straight trading days

-- Worst nine day stretch since the nine days ending June 19, 2020, when it fell 8.17%

-- Down 9.1% month-to-date

-- Down 2.02% year-to-date

-- Down 20.83% from its all-time closing high of $76.77 on July 14, 2016

-- Up 2.31% from 52 weeks ago (Sept. 17, 2020), when it closed at $59.40

-- Down 12.31% from its 52-week closing high of $69.31 on Aug. 3, 2021

-- Up 5.26% from its 52-week closing low of $57.74 on Oct. 6, 2020

-- Traded as low as $60.67; lowest intraday level since March 15, 2021, when it hit $60.29

-- Down 2.15% at today's intraday low

All data as of 11:08:53 AM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

09-16-21 1128ET

All news about BRISTOL-MYERS SQUIBB COMPANY
10/25GLOBAL MARKETS LIVE : HSBC, PayPal, Tesla, Daimler, Intel...
10/25TCR2 THERAPEUTICS : Initiates Clinical Trial Partnership With Bristol Myers Squibb to Eval..
MT
10/25Aurinia Pharmaceuticals Shares Rally on Report of Bristol Myers Interest
DJ
10/25BRISTOL MYERS SQUIBB : Announces Earnings Call Time Change; Third Quarter 2021 Earnings Ca..
BU
10/25BRISTOL MYERS SQUIBB : TCR▓ Therapeutics Announces Clinical Trial Collaboration Agreement ..
AQ
10/22BRISTOL-MYERS CVR INVESTORS : December 6, 2021 Filing Deadline in Class Action – Con..
BU
10/22BRISTOL MYERS SQUIBB : Reportedly Approaches Aurinia Pharmaceuticals For Takeover; Aurinia..
MT
10/22AURINIA PHARMACEUTICALS : Bristol-Myers Reportedly Makes Takeover Approach to Aurinia Phar..
MT
10/22Lymphoma Hub maintains its focus on raising the levels of global knowledge of lymphoma ..
AQ
10/22BRISTOL MYERS SQUIBB : Receives European Commission Approval for Opdivo (nivolumab) + Chem..
AQ
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 329 M - -
Net income 2021 6 492 M - -
Net Debt 2021 28 443 M - -
P/E ratio 2021 20,1x
Yield 2021 3,40%
Capitalization 128 B 128 B -
EV / Sales 2021 3,39x
EV / Sales 2022 3,06x
Nbr of Employees 30 250
Free-Float 76,0%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 57,81 $
Average target price 74,62 $
Spread / Average Target 29,1%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY-6.80%128 460
JOHNSON & JOHNSON4.26%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.25%241 929
ELI LILLY AND COMPANY45.14%222 158